Zeimet A G, Stadlmann S, Natoli C, Widschwendter M, Hermann M, Abendstein B, Daxenbichler G, Offner F A, Iacobelli S, Marth C
Department of Obstetrics and Gynecology, University Hospital Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
Anticancer Res. 2000 Nov-Dec;20(6B):4507-11.
The tumor associated antigen 90K is known to possess cytokine-like modulatory properties on the cellular immune system, whereby accessory cells are the primary target of this molecule. In 67 ovarian cancer patients presenting with significant amounts of ascites, immunostimulatory protein 90K was detected in all ascitic fluid samples examined. Furthermore, 90K levels correlated to ascitic s-IL-2R content. To elucidate the source of protein 90K in ascitic fluid; its in vitro release was investigated in primary cultured normal human peritoneal mesothelial cells (HPMC). Peritoneal mesothelium was found to produce five-fold more 90K than ovarian cancer cells. Release of protein 90K was significantly increased by treatment with IFN-gamma in both mesothelial and ovarian cancer cells. In contrast neither IL-1 beta nor TNF-alpha treatment consistently influenced the secretion of 90K in either cell type.
肿瘤相关抗原90K已知对细胞免疫系统具有细胞因子样调节特性,其中辅助细胞是该分子的主要靶标。在67例出现大量腹水的卵巢癌患者中,在所检测的所有腹水样本中均检测到免疫刺激蛋白90K。此外,90K水平与腹水中可溶性白细胞介素-2受体(s-IL-2R)含量相关。为了阐明腹水中蛋白90K的来源,对原代培养的正常人腹膜间皮细胞(HPMC)中其体外释放情况进行了研究。发现腹膜间皮产生的90K比卵巢癌细胞多五倍。用γ干扰素处理后,间皮细胞和卵巢癌细胞中蛋白90K的释放均显著增加。相比之下,白细胞介素-1β和肿瘤坏死因子-α处理均未持续影响任一细胞类型中90K的分泌。